The FDA is cracking down on supplements with unprecedented intensity, shifting enforcement away from manufacturing issues toward the marketing claims companies make online and on social media. Through late July 2026, the agency issued 363 warning letters, surpassing the same period in 2025 (354), 2024 (321), and 2023 (293), with June alone producing 86 letters, the busiest month of the year.

What's Driving the FDA's Enforcement Surge?

The shift in FDA enforcement priorities reflects a fundamental change in how regulators investigate supplements and dietary products. Historically, the agency focused on manufacturing problems like sanitation failures and Good Manufacturing Practice (GMP) violations. Today, marketing claims have become one of the fastest-growing enforcement priorities, with investigators increasingly relying on publicly available materials rather than on-site factory inspections.

Company websites were cited in 218 of the 247 published FDA warning letters analyzed in 2026. Social media platforms get scrutinized too: Facebook appeared in 22 warning letters and Instagram in 12 during 2024, then 16 and 19 respectively in 2025, along with Amazon product listings. In one April 2026 letter to a supplement marketer, the FDA noted that it had reviewed the company's Facebook page while cataloging heart-disease and diabetes treatment claims on the website it linked to.

Why Are Undeclared Ingredients Still the Top Problem?

Despite new enforcement priorities, the most common compliance failures remain surprisingly familiar. Many recalls still come down to one fundamental problem: the label does not accurately reflect what is inside the package. Undeclared allergens account for 85 of the 237 FDA food and supplement recalls tracked so far in 2026, more than any other cause.

The breakdown reveals a checklist of quality-control gaps across the industry:

• Milk: Missed on 20 labels, making it the most frequently undeclared allergen
• Soy: Undeclared on 19 product labels
• Sesame: Undeclared on 9 labels, continuing to trip up brands three years after the FASTER Act made it the ninth major allergen
• Wheat: Undeclared on 9 labels
• Egg: Undeclared on 8 labels
• Peanut: Undeclared on 6 labels

In late July, Lidl US recalled its imported private-label shortbread cookies for undeclared wheat, soy, milk, egg, and tree nuts all at once. Sesame remains particularly problematic; 2026 opened with a hummus maker recalling multiple varieties for undeclared sesame.

How Are Misleading Marketing Claims Becoming a Regulatory Target?

The clearest example of FDA's new enforcement direction is its campaign against compounded weight-loss products. The agency issued more than 50 warning letters to telehealth companies during two coordinated enforcement waves in 2026, challenging claims that compounded semaglutide and tirzepatide products were equivalent to brand-name drugs or "FDA-approved." The June letters quote the companies' own websites line by line.

This same enforcement logic extends to supplements. A July letter to a supplement maker shows the pattern: neuropathy-relief claims on the company's website turned its dietary supplements into unapproved new drugs in the FDA's eyes. For supplement brands, this means every consumer-facing claim, whether it appears on a website, retailer listing, email campaign, or Instagram post, has become part of the regulatory review.

Steps to Ensure Supplement Compliance in 2026

• Audit All Marketing Materials: Review every claim on your website, social media accounts, email campaigns, and retailer listings to ensure they do not suggest the supplement treats, prevents, or cures disease. The FDA now systematically reviews these public materials as part of its enforcement strategy.
• Verify Ingredient Accuracy: Conduct thorough quality-control checks to confirm that every ingredient listed on the label is actually present in the product and that all allergens are clearly disclosed. Undeclared allergens remain the leading cause of recalls.
• Strengthen Supplier Oversight: Implement Foreign Supplier Verification Program (FSVP) protocols to monitor ingredient sources. Warning letters citing FSVP violations have risen from 18 at this point last year to 42 in 2026, making supplier verification one of the agency's largest enforcement priorities.

The financial stakes are substantial. Industry estimates place the average direct cost of a recall at roughly $10 million before legal expenses, lost sales, and damage to brand reputation.

What Role Are Lawsuits Playing in Supplement Enforcement?

The plaintiffs' bar is running the same enforcement playbook as the FDA. Federal dockets show 93 baby-food heavy-metals suits filed in 2026 against just 4 in the same window last year, a 99-case cluster naming the category's biggest manufacturers. Suits challenging "natural" and "organic" label claims number 14, with 6 filed this year versus 1 by this point in 2025. Class-action complaints increasingly quote the same public marketing language the FDA quotes, so one weak claim now draws fire from two directions.

For supplement makers, the message is clear: the era of lenient enforcement is over. The FDA is no longer waiting for manufacturing disasters to strike. Instead, regulators are proactively scanning websites, social media, and retailer listings for any claim that crosses the line from dietary supplement into drug territory. Companies that fail to align their marketing with regulatory reality face not just FDA warning letters, but coordinated litigation from consumer attorneys as well.